Abstract:T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity. Numerous strategies are being developed to overcome these barriers, which include improving culture conditions and manufacturing protocols, implementing novel CAR designs, and novel approaches to engineering the T cell phenotype. In this review, we describe the various emerging strategies to improve CAR T cell therapy for solid tumours. We specifically focus on new strategies to modulate cell function and fate that have precipitated from the growing knowledge of transcriptional circuits driving T cell differentiation, with the ultimate goal of driving more productive anti-tumour T cell immunity. Evidence shows that enrichment of particular phenotypic subsets of T cells in the initial cell product correlates to improved therapeutic responses and clinical outcomes. Furthermore, T cell exhaustion and poor persistence are major factors limiting therapeutic efficacy. The latest preclinical work shows that targeting specific master regulators and transcription factors can overcome these key barriers, resulting in superior T cell therapeutic products. This can be achieved by targeting key transcriptional circuits promoting memory-like phenotypes or sustaining key effector functions within the hostile tumour microenvironment. Additional discussion points include emerging considerations for the field such as (i) targeting permutations of transcription factors, (ii) transient expression systems, (iii) tissue specificity, and (iv) expanding this strategy beyond CAR-T cell therapy and cancer.

New opportunities to overcome T cell dysfunction: the role of transcription factors and how to target them

T cell dysfunction and therapeutic intervention in cancer

Tumor Immune Checkpoints and Their Associated Inhibitors

Reversing T-cell Dysfunction and Exhaustion in Cancer

Beyond immune checkpoint blockade: emerging immunological strategies

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

T Cell Dysfunction and Exhaustion in Cancer

Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade

T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano‐Delivery Systems for Enhanced Immunotherapy

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms

The Interplay between T Cells and Cancer: The Basis of Immunotherapy

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions